Cerevel Therapeutics (CERE) Stock Price, News & Analysis

Company Overview

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $44.96 to $44.96
• 50-Day Range: $40.30 to $44.96
• 52-Week Range: $19.59 to $44.99
• Volume: N/A
• Average Volume: 1.71 million shs
• Market Capitalization: $8.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CERE Stock Analysis - Frequently Asked Questions

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) issued its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.02.
Read the conference call transcript.

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cerevel Therapeutics investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), First Solar (FSLR) and Datadog (DDOG).

Company Calendar

• Last Earnings: 11/01/2023
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Coal & Consumable Fuels
• Current Symbol: NASDAQ:CERE
• CIK: 767884
• Web: ceres.net
• Phone: 844-304-2048
• Fax: N/A
• Employees: 300
• Year Founded: 2018

Profitability

• EPS (Trailing Twelve Months): ($2.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$432.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -98.94%
• Return on Assets: -45.07%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 10.22
• Quick Ratio: 10.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.71 per share
• Price / Book: 12.12

Miscellaneous

• Outstanding Shares: 182,200,000
• Free Float: 172,903,000
• Market Cap: $8.19 billion
• Optionable: Optionable
• Beta: 1.40